Dated: January 14, 2002.

LaVerne Y. Stringfeild,

Director, Office of Federal Advisory Committee Policy, NIH.

[FR Doc. 02–1434 Filed 1–18–02; 8:45 am]

BILLING CODE 4140–01–M

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health

National Heart, Lung, and Blood Institute; Notice of Closed Meeting

Pursuant to section 10(d) of the Federal Advisory Committee Act, as amended (5 U.S.C. Appendix 2), notice is hereby given of the following meeting.

The meeting will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., as amended. The grant applications and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the grant applications, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy.

Name of Committee: Clinical Trials Review Committee.

Date: February 25–26, 2002.

Time: February 25, 2002, 8:00 AM to Adjournment.

Agenda: To review and evaluate grant applications.

Place: Hilton Hotel, 8727 Colesville Road, Silver Spring, MD 20910.

Contact Person: Joyce A. Hunter, PhD, Review Branch, Room 7129, Division of Extramural Affairs, National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, MD 20892–7924, 301/435–0277.

(Catalogue of Federal Domestic Assistance Program Nos. 93.233, National Center for Sleep Disorders Research; 93.837, Heart and Vascular Diseases Research; 93.838, Lung Diseases Research; 93.839, Blood Diseases and Resources Research, National Institutes of Health, HHS)

Dated: January 14, 2002.

LaVerne Y. Stringfield,

Director, Office of Federal Advisory Committee Policy.

[FR Doc. 02–1432 Filed 1–18–02; 8:45 am]

BILLING CODE 4140–01–M

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health

National Heart, Lung, and Blood Institute; Notice of Closed Meeting

Pursuant to section 10(d) of the Federal Advisory Committee Act, as amended (5 U.S.C. Appendix 2), notice is hereby given of the following meeting.

The meeting will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., as amended. The grant applications and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the grant applications, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy.

Name of Committee: National Heart, Lung, and Blood Institute Special Emphasis Panel Demonstration & Education Research.

Date: February 12, 2002.

Time: 10:00 AM to 6:00 PM.

Agenda: To review and evaluate grant applications.

Place: Hilton Hotel, 8727 Colesville Road, Silver Spring, MD 20910.

Contact Person: Zoe E. Huang, MD, Review Branch, Division of Extramural Affairs, National Heart, Lung, and Blood Institute, Bethesda, MD 20892–7924, (301) 435–0287, *huangz@nih.gov*.

(Catalogue of Federal domestic Assistance Program Nos. 93.233, National Center for Sleep Disorders Research; 93.837, Heart and Vascular Diseases Research; 93.838, Lung Diseases Research; 93.839, Blood Diseases and Resources Research, National Institutes of Health, HHS)

Dated: January 14, 2002.

LaVerne Y. Stringfield,

Director, Office of Federal Advisory Committee Policy.

[FR Doc. 02–1433 Filed 1–18–02; 8:45 am]

BILLING CODE 4140–01–M

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health

Prospective Grant of Exclusive License: Development of Diagnostic Tests for *Plasmodium falciparum* Caused Malaria

AGENCY: National Institutes of Health, Public Health Service, DHHS.

ACTION: Notice.

SUMMARY: This is notice, in accordance with 35 U.S.C. 209(c)(1) and 37 CFR 404.7(a)(1)(i), that the National Institutes of Health (NIH), Department of Health and Human Services, is contemplating the grant of an exclusive license concerning the inventions embodied in:

USSN 5,130,416 (USPA 07/518,299, filed 05/03/90) issued July 14, 1992

USSN 5,296,382 (USPA 07/791,392, filed 11/14/91) issued March 22, 1994

USSN 5,476,785 (USPA 08/161,406, filed 12/06/93) issued December 19, 1995

all entitled ''Recombinant DNA clone containing a genomic fragment of PfHRP–II gene from Plasmodium falciparum'' and invented by Thomas E. Wellems and Russell J. Howard, to Akers Laboratories, Inc., a diagnostic company having a place of business in Thorofare, N.J. The United States of America is an assignee to the patent rights of these inventions.

The contemplated exclusive license may be limited to the development of diagnostic tests for *Plasmodium falciparum*-caused Malaria for sales in the United States. A nonexclusive license of the present inventions to make and use in the United States but to sell in territories outside of the United States is available to other licensees.

DATES: Only written comments and/or applications for a license, which are received by the NIH Office of Technology Transfer on or before March 25, 2002, will be considered.

ADDRESSES: Requests for a copy of the patents, inquiries or comments relating to the contemplated license should be directed to: Uri Reichman, Ph.D., Technology Licensing Specialist, Office of Technology Transfer, National Institutes of Health, 6011 Executive Boulevard, Suite 325, Rockville, MD 20852–3804; Telephone: (301) 496–7056, ext. 240; Facsimile: (301) 402–0220; e-mail: *reichmau@od.nih.gov*.

SUPPLEMENTARY INFORMATION: The inventions included in the prospective license relates to the isolation of clones of DNA from the malaria-causing parasite *Plasmodium falciparum* (*P. falciparum*) that encode a histidine-rich protein (designated name PfHRP–II) from this organism. PfHRP–II is expressed on P. falciparum-infected erythrocytes, and released from the infected host erythrocytes into the body fluids. The inventions describe the cloning procedure and the characterization of the coding sequence as well as that of the encoded protein and the antibodies made against it. The inventions can be utilized in the development of diagnostic tests for malaria as contemplated by the

prospective licensee, or for vaccine development against malaria.

The prospective exclusive license will be royalty-bearing and will comply with the terms and conditions of 35 U.S.C. 209 and 37 CFR 404.7. The prospective exclusive license may be granted unless, within 60 days from the date of this published Notice, NIH receives written evidence and argument that establishes that the grant of the license would not be consistent with the requirements of 35 U.S.C. 209 and 37 CFR 404.7.

Properly filed competing applications for a license filed in response to this notice will be treated as objections to the contemplated license. Comments and objections submitted in response to this notice will not be made available for public inspection, and, to the extent permitted by law, will not be released under the Freedom of Information Act, 5 U.S.C. 552.

Dated: January 14, 2002.

Jack Spiegel,

Director, Division of Technology Development and Transfer, Office of Technology Transfer.

[FR Doc. 02–1438 Filed 1–18–02; 8:45 am]

BILLING CODE 4140–01–P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health

Prospective Grant of Exclusive License: Specific Killing of HIV Infected Lymphocytes by a Recombinant Immunotoxin Directed Against the HIV–1 GP 120 Envelope Glycoprotein

AGENCY: National Institutes of Health, Public Health Service, and DHHS.

ACTION: Notice.

SUMMARY: This notice, in accordance with 35 U.S.C. 209(c)(1) and 37 CFR 404.7(a)(1) (i), that the National Institutes of Health, Department of Health and Human Services, is contemplating the grant of an exclusive patent license to practice the inventions embodied in U.S. Patent Application, 60/088,860 (refiled): ''Specific Killing of HIV Infected Lymphocytes by a Recombinant Immunotoxin Directed Against the HIV–1 GP 120 Envelope Glycoprotein'' (DHHS Ref. E–201–98/0); PCT Patent Application, PCT/US99/12909 (refiled): ''Specific Killing of HIV Infected Lymphocytes by a Recombinant Immunotoxin Directed Against the HIV–1 GP 120 Envelope Glycoprotein'' (DHHS Ref. E–201–98/1); Related Foreign Filed National Stage Applications claiming priority to 60/088,860, (pending) in Europe, Canada, Japan, Australia and the National Stage United States Application [S/N 09/673,707 (DHHS Ref. E–201–98/2)]: ''Specific Killing of HIV Infected Lymphocytes by a Recombinant Immunotoxin Directed Against the HIV–1 GP 120 Envelope Glycoprotein;'' US Patent 4,892,827, S/N 06/911,227: ''Recombinant Pseudomonas Exotoxin: Construction of an Active Immunotoxin with Low Side Effects,''—excluding any foreign equivalents corresponding to 4,892,827 (DHHS Ref. E–385–86/0); US Patent 5,747,654, S/N 08/077,252: ''Recombinant Disulfide-Stabilized Polypeptide Fragments Having Binding Specificity.'' PHS is an owner of corresponding foreign rights in national phase prosecution in Canada, Australia, Japan, and the European Patent Office. (DHHS Ref. E–163–93/0); US Patent 6,147,203, S/N 09/002,753: ''Recombinant Disulfide-Stabilized Polypeptide Fragments Having Binding Specificity,'' (DHHS Ref. E–163–93/4); US Patent 6,051,435, S/N 07/865,722: ''Recombinant Antibody-Toxin Fusion Protein,'' (DHHS Ref. E–135–89/1) US Patent 5,863,745, S/N 08/461,825: ''Recombinant Antibody-Toxin Fusion Protein,'' (DHHS Ref. E–135–89/2); and US Patent 5,696,237, S/N 08/463,163: ''Recombinant Antibody-Toxin Fusion Protein,'' (DHHS Ref. E–135–89/3) to IVAX Corporation which is located in Miami, Florida. The patent rights in these inventions have been assigned to the United States of America.

The prospective exclusive license territory will be worldwide and the field of use may be limited to human therapeutics for the treatment of HIV-associated diseases using 3B3(scFv)-PE38 or 3B3(dsFv)-PE38 immunotoxin constructs.

DATES: Only written comments and/or license applications which are received by the National Institutes of Health on or before March 25, 2002 will be considered.

ADDRESSES: Requests for copies of the patent, inquiries, comments and other materials relating to the contemplated exclusive license should be directed to: Richard U. Rodriguez, M.B.A., Technology Licensing Specialist, Office of Technology Transfer, National Institutes of Health, 6011 Executive Boulevard, Suite 325, Rockville, MD. 20852–3804; Telephone: (301) 496–7056, x287; Facsimile: (301) 402–0220; and E-mail: *rodrigur@od.nih.gov.*

SUPPLEMENTARY INFORMATION: The primary technology is directed to an immunotoxin that specifically binds to and kills cells expressing an HIV gp-120 coat protein. The immunotoxin comprises an anti-gp-120 antibody directed to the conserved CD4 binding site of gp 120 attached to a cytotoxin (e.g., a Pseudomonas exotoxin). In one preferred embodiment, the immunotoxin is a recombinantly expressed fusion protein comprising a disulfide linked Fv region attached to a modified Pseudomonas exotoxin [i.e., 3B3 (Fv)-PE38]. The technology is also directed to: a pharmaceutical composition; a composition of the immunotoxin; methods for killing HIV infected cells; and to a kit for killing cells that display a gp-120 protein.

The prospective exclusive license will be royalty bearing and will comply with the terms and conditions of 35 U.S.C. 209 and 37 CFR 404.7. The prospective exclusive license may be granted unless within sixty (60) days from the date of this published notice, the NIH receives written evidence and argument that establish that the grant of the license would not be consistent with the requirements of 35 U.S.C. 209 and 37 CFR 404.7.

Applications for a license in the field of use filed in response to this notice will be treated as objections to the grant of the contemplated exclusive license. Comments and objections submitted to this notice will not be made available for public inspection and, to the extent permitted by law, will not be released under the Freedom of Information Act, 5 U.S.C. 552.

Dated: January 14, 2002.

Jack Spiegel,

Director, Division of Technology Development and Transfer, Office of Technology Transfer.

[FR Doc. 02–1437 Filed 1–18–02; 8:45 am]

BILLING CODE 4140–01–P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Substance Abuse and Mental Health Services Administration

Notice of a Meeting

Pursuant to Pub. L. 92–463, notice is hereby given of a meeting of the Substance Abuse and Mental Health Services Administration (SAMHSA) National Advisory Council in February 2002.

The SAMHSA National Advisory Council meeting will be open and will include a presentation by the New SAMHSA Administrator on his Vision and Priorities for the Agency, discussions on the Agency's restructuring and delayering plans, on the National Summit on Terrorism/BioTerrorism Response Activities, on the President's new Mental Health Commission, on FY 2002 appropriation